Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cosmo Pharmaceuticals N.V.    COPN   NL0011832936

COSMO PHARMACEUTICALS N.V.

(COPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Cosmo Pharmaceuticals N : Acacia Pharma completes drawdown from EUR25 million loan facility from Cosmo Pharmaceuticals to support US launches of BARHEMSYS and BYFAVO

10/12/2020 | 10:06am EST

Cambridge - Acacia Pharma Group plc ('Acacia Pharma', the 'Group' or the 'Company') (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that it has drawn down the remaining EUR10 million available under its unsecured EUR25 million loan facility with Cosmo Technologies Limited, a wholly-owned subsidiary of Cosmo Pharmaceuticals N.V.

The Company plans to deploy this capital to support its ongoing US launches of BARHEMSYS (amisulpride injection) for postoperative nausea & vomiting and BYFAVO (remimazolam for injection) for procedural sedation.

'We are extremely grateful for the continued support from our partner, Cosmo. This capital injection, in addition to the placing funds raised recently, significantly strengthens our financial position and will help us to further fund the launches of BARHEMSYS and BYFAVO in the US,' said Acacia Pharma's CEO, Mike Bolinder. 'We are delighted with the progress we have made in 2020: BARHEMSYS was launched in August and we are on track to launch BYFAVO by the end of the year. We see great potential in both products for addressing the care of patients undergoing medical procedures and for improving patient throughput in hospitals. We will be working hard over the next 12 months, during our initial launch phase, to ensure formulary access for our products as a key first step in establishing a base from which to drive sales in hospitals in the US.'

Acacia Pharma announced on 10 January 2020 that it had entered a strategic in-licensing transaction with Cosmo (click here to access the announcement). The agreement granted Acacia Pharma exclusive US commercialization rights to BYFAVO and was made alongside an equity investment and debt facility by Cosmo to finance the commercialization of both BARHEMSYS and BYFAVO.

Forward looking statements

This announcement includes forward-looking statements, which are based on current expectations and projections about future events. These statements may include, without limitation, any statements preceded by, followed by or including words such as 'believe', 'expect', 'intend', 'may', 'plan', 'will', 'should', 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements may and often do differ materially from actual results. These forward-looking statements are subject to risks, uncertainties and assumptions about the Company and its subsidiaries and investments, including, among other things, the development of its business, trends in its operating industry, and future capital expenditures and acquisitions. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Any forward-looking statements reflect the Company's current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Group's business, results of operations, financial position, prospects, growth or strategies and the industry in which it operates. Save as required by law or applicable regulation, the Company and its affiliates expressly disclaim any obligation or undertaking to update, review or revise any forward-looking statement contained in this announcement whether as a result of new information, future developments or otherwise. Forward-looking statements speak only as of the date they are made.

Contact:

Gary Gemignani

Tel: +44 (0) 1223 919760

Email: IR@acaciapharma.com

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
ACACIA PHARMA GROUP 1.24% 2.455 Delayed Quote.16.35%
COSMO PHARMACEUTICALS N.V. -1.63% 84.5 Delayed Quote.11.99%
All news about COSMO PHARMACEUTICALS N.V.
12/01Cosmo Pharmaceuticals appoints new Chief Medical Officer
TE
12/01Cosmo Pharmaceuticals ernennt neuen Chief Medical Officer
TE
11/24COSMO PHARMACEUTICALS N : Announces Senior Leadership Changes
AQ
11/23Cosmo Pharmaceuticals Announces Senior Leadership Changes
TE
11/23Cosmo Pharmaceuticals kündigt Wechsel im Führungsteam an
TE
11/20COSMO PHARMACEUTICALS N : announces expansion of agreement with Dr. Falk Pharma ..
AQ
11/19Cosmo Pharmaceuticals announces expansion of agreement with Dr. Falk Pharma f..
TE
11/18COSMO PHARMACEUTICALS N : announces approval of Eleview in Japan
AQ
11/17Cosmo Pharmaceuticals announces approval of Eleview® in Japan
TE
10/12COSMO PHARMACEUTICALS N : Acacia Pharma completes drawdown from EUR25 million lo..
AQ
More news
Financials
Sales 2020 53,1 M 64,2 M 64,2 M
Net income 2020 -8,53 M -10,3 M -10,3 M
Net cash 2020 51,0 M 61,6 M 61,6 M
P/E ratio 2020 -132x
Yield 2020 -
Capitalization 1 125 M 1 356 M 1 359 M
EV / Sales 2020 20,2x
EV / Sales 2021 16,7x
Nbr of Employees 261
Free-Float 45,8%
Chart COSMO PHARMACEUTICALS N.V.
Duration : Period :
Cosmo Pharmaceuticals N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COSMO PHARMACEUTICALS N.V.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 102,69 €
Last Close Price 77,77 €
Spread / Highest target 43,1%
Spread / Average Target 32,0%
Spread / Lowest Target 21,3%
EPS Revisions
Managers
NameTitle
Alessandro E. Della Chà Chief Executive Officer & Executive Director
Mauro Severino Ajani Executive Chairman
Giuseppe Cipriano Chief Operating Officer
Niall Donnelly Chief Financial Officer & Head-Investor Relations
Davide Malavasi Director-Qualified Person & Technical
Sector and Competitors
1st jan.Capitalization (M$)
COSMO PHARMACEUTICALS N.V.11.99%1 356
JOHNSON & JOHNSON-0.82%380 876
ROCHE HOLDING AG-4.76%282 467
PFIZER, INC.3.21%212 942
NOVARTIS AG-10.48%206 479
MERCK & CO., INC.-11.61%203 389